SCHEMBL4059012

SCHEMBL4059012

CC(C)(C)OC(=O)NCCNC(=O)c1ccccc1Br

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.56
HTT P42858 2/20 0.56
RAB9A P51151 2/20 0.56
MEN1 O00255 1/20 0.56
NPC1 O15118 1/20 0.56
KMT2A Q03164 1/20 0.56
NLRP3 Q96P20 1/20 0.51
KCNA5 P22460 1/20 0.51
MAPT P10636 2/20 0.50
ALDH1A1 P00352 3/20 0.48
MALT1 Q9UDY8 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
GAA P10253 2/20 0.47
BCHE P06276 1/20 0.46
HCRTR1 O43613 1/20 0.46
IDO1 P14902 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28027633 0.90 KCNA5 (0.56) HTTMEN1KMT2AKCNA5MALT1
SCHEMBL1657927 0.84 ESRRG (0.56) HPGDHTTMEN1NPC1KMT2A
SCHEMBL9540574 0.83 KCNA5 (0.58) HTTRAB9AMEN1NPC1KMT2A
SCHEMBL30737331 0.82 MEN1 (0.47) HPGDHTTRAB9AMEN1NPC1
SCHEMBL9743749 0.82 KCNA5 (0.56) HTTMEN1KMT2AKCNA5MALT1
SCHEMBL14690580 0.82 CRBN (0.51) HPGDHTTKCNA5ALDH1A1MALT1
SCHEMBL25278729 0.81 HTT (0.51) HPGDHTTRAB9AMEN1NPC1
SCHEMBL25470877 0.80 MALT1 (0.54) HTTRAB9AMEN1NPC1KMT2A
SCHEMBL1754810 0.79 POLB (0.58) HPGDRAB9ANPC1MALT1GAA
SCHEMBL29793814 0.78 NQO2 (0.56) HTTRAB9AMEN1NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7507753-B2 melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2009-03-24 US disclosed
US-20050096359-A1 melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-05 US disclosed
EP-1466904-A1 BIARYL COMPOUND AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096359-A1 melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride MC4R, MC3R, MC1R HPGD 3319/4885HTT 636/4885RAB9A 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.